Navigation Links
VIA Pharmaceuticals Secures Financing Up to $10.0 Million
Date:3/12/2009

SAN FRANCISCO, March 12 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced it has entered into a $10.0 million secured note purchase agreement (together with certain ancillary agreements, the "Loan Agreement") with Bay City Capital Fund IV, L.P. and one of its affiliates (collectively, "Lender"), the Company's principal stockholder. The Company borrowed the first tranche of $2.0 million on March 12, 2009. Subject to Lender approval, the Company may borrow up to an additional $8.0 million pursuant to the terms of the Loan Agreement.

"This Loan Agreement reflects the continuing support and confidence of Bay City Capital in our lead program VIA-2291 for the treatment of cardiovascular disease caused by atherosclerosis, by targeting inflammation in the blood vessel wall, an underlying cause of atherosclerosis," said Lawrence K. Cohen, Ph.D., Chief Executive Officer of VIA Pharmaceuticals. "We are excited about the potential of VIA-2291 which is being demonstrated in the data from our ongoing Phase 2 trials, and intend to pursue strategic opportunities to partner and collaborate with large biotechnology or pharmaceutical companies to further develop this exciting compound."

The Loan Agreement provides for borrowings of up to $10.0 million, which bear interest at 15% per annum. Borrowings subsequent to the initial $2.0 million borrowing are at the discretion of the Lender. The Company's obligations under the Loan Agreement are secured by a first priority lien on all of the Company's assets. All outstanding principal and accrued interest are due on September 14, 2009, subject to certain repayment acceleration provisions set forth in the Loan Agreement, including, without limitatio
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
2. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
3. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
4. Onyx Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
5. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
6. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
7. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
8. AcelRx Pharmaceuticals Hires Mark Evashenk as Vice President of Clinical Operations
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
10. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
11. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
Post Your Comments:
*Name:
*Comment:
*Email: